Expertise: Payer Market Research, Biosimilars, Contracting, Reimbursement and Rebates, Policy and Regulation
Samantha Ngan is an associate market research manager at MMIT. With expertise in quantitative research methods, Samantha uses skills from the intersection of analytics and language to provide strategic insights to clients. She earned bachelor’s degrees in math and linguistics from UC San Diego and recently finished a master’s in business analytics from Duke University.
Apples to Apples: Stelara Biosimilars and the Fight for Market Share
Over the next five years, 88 biologics—including several blockbuster agents like Eliquis, Keytruda, Opdivo, and Darzalex—are facing a loss of exclusivity, representing an estimated market of more than $100 billion.
As payers grapple with their ever-increasing spend on healthcare services, many are entering into various arrangements with pharma manufacturers to help mitigate their risk when paying for cell, gene and specialty therapies—which often have price tags ranging from several hundred thousand to millions of dollars.
For the past decade, biosimilar adoption in the U.S. has proceeded at a relatively slow pace, due in large part to limited financial rebates for payers and provider preferences for biologics. Recent research suggests that utilization is finally picking up steam as more health plans place both biosimilars and their reference biologics on preferred formulary tiers.
How Will the Launch of Humira Biosimilars Impact Patients, Payers and IDNs?
Across indications, biosimilar uptake is rapidly accelerating, with the number of biologics facing biosimilar competition more than doubling by 2026. This year’s impending launch of adalimumab biosimilars will serve as a case study for manufacturers, who will be studying the market’s response.
